ClinicalTrials.gg
CompletedNCT02291289MODULUpdated May 6, 2024Results posted

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

A Phase 2 interventional study of Cetuximab and FOLFOX induction regimen in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 154 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,044
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
9th of 185
1,044 · median 60
Started
2015
with 4 others
Phase 2
107 of 187
20 open now
Registered
108th of 187
by date
Lead sponsor
3 of 187
Hoffmann-La Roche

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 9th largest by enrollment of the 185 interventional ones that give a count, is one of 5 that started in 2015, is one of 107 in phase 2, and was the 108th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PS of less than or equal to (\<=) 2
  • At least 16 weeks of at time of entry into the study
  • confirmed colorectal cancer (CRC) with mCRC confirmed radiologically
  • Measureable, unresectable disease according to 1.1
  • No prior chemotherapy for CRC in the setting
  • Archival tumor formalin-fixed paraffin-embedded tissue block from the primary tumor obtained at the time of the initial diagnosis is available
  • Adequate hematological, liver and renal function
  • Agreement to use highly effective measures of

Exclusion criteria

Exclusion Criteria for All Participants:

  • Less than 6 months from completion of any prior or adjuvant chemotherapy, radiotherapy
  • Prior or current treatment with bevacizumab or any other anti-angiogenic drug (vascular endothelial growth factor or vascular endothelial growth factor receptor therapies or tyrosine kinase inhibitors)
  • Current or recent (within 10 days of study enrollment) use of aspirin (more than [>] 325 milligrams per day [mg/day]), clopidogrel (> 75 mg/day), or current or recent (within 10 days prior to the start of study induction treatment) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes (prophylactic uses allowed)
  • Active infection requiring intravenous antibiotics at the start of study induction treatment
  • Previous or concurrent , except for adequately treated basal or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the participant has been disease-free for 5 years prior to study entry
  • Inadequately controlled hypertension; prior history of hypertensive crisis or hypertensive encephalopathy
  • (active) cardiovascular disease, for example cerebrovascular accidents \<= 6 months prior to start of study induction treatment, myocardial infarction \<= 6 months prior to study enrollment, unstable angina, (NYHA) Functional Classification Grade II or greater congestive heart failure, or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment
  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months of start of study induction treatment
  • Active symptomatic or untreated central nervous system (CNS) ; CNS disease other than supratentorial or cerebellar metastases (in other words, patients with metastases to midbrain, pons, medulla or spinal cord are excluded); history of or known carcinomatous meningitis
  • Known to any component of any of the study induction or maintenance treatment medications
  • Pregnancy or lactation

Exclusion Criteria for Participants in Cohort 1 (MP):

  • Inability to swallow pills
  • nausea and vomiting, malabsorption, external biliary shunt or significant bowel resection that would preclude adequate absorption
  • History or presence of clinically significant ventricular or atrial dysrhythmias
  • (QTc) interval >= 450 millisecond assessed within 3 weeks prior to randomization, long QT syndrome or, uncorrectable electrolyte abnormalities (including magnesium) or requirement for medicinal products known to prolong the QT interval
  • PS > 2

Exclusion Criteria for Participants in Cohort 2 (MP):

  • History of disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
  • Prior bone marrow transplantation or prior solid organ transplantation
  • History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis at most recent chest imaging (computed tomography [CT] scan or magnetic resonance imaging [MRI])
  • Positive test for (HIV)
  • Active virus (HBV) or virus (HCV) at Screening
  • Active tuberculosis
  • Severe infection within 4 weeks prior to start of maintenance treatment including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia; has signs or symptoms of significant infection or has received oral or IV antibiotics within 2 weeks prior to start of maintenance treatment
  • Administration of a live, attenuated vaccine within 4 weeks prior to start of maintenance treatment or anticipation that such a will be required during the remainder of the study
  • Prior treatment with cluster of differentiation (CD) 137 agonists, anti-cytotoxic T-lymphocyte-associated antigen (CTLA) 4, anti-programmed death-1 (), or anti-programmed death-ligand 1 (PD-L1) therapeutic antibody or pathway-targeting agents
  • Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 4 weeks or five half-lives of the drug, whichever is longer, prior to start of maintenance treatment
  • Treatment with systemic or other systemic medications within 2 weeks prior to start of maintenance treatment, or anticipated requirement for systemic immunosuppressive medications during the remainder of the study
  • If receiving receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor (for example, denosumab) and unwilling to adopt alternative treatment such as bisphosphonates while receiving atezolizumab

Exclusion Criteria for Participants in Cohort 3 (MP):

  • Inability to swallow pills
  • (LVEF) less than (\<) 50 percent (%) as assessed after completion of induction treatment by either 2-dimensional echocardiogram or multiple-gated acquisition
  • Clinically significant cardiovascular disease, including unstable angina, history of or active congestive heart failure of ≥ NYHA Grade 2, history of or ongoing serious cardiac arrhythmia requiring treatment (except for controlled atrial fibrillation and/or paroxysmal supraventricular tachycardia).
  • Current uncontrolled hypertension with or without medication
  • Current dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy
  • Insulin-dependent diabetes
  • Current known infection with HIV, HBV, or HCV (active infection or carriers)
  • Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or chemically related analogues, such as brivudine
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, or ulcerative colitis
  • Known hypersensitivity to murine proteins

Exclusion Criteria for Participants in Cohort 4 (MP):

  • Inability to swallow medications
  • History of autoimmune disease including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
  • History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on most recent chest imaging (CT scan or MRI)
  • Malabsorption condition that would alter the absorption of orally administered medications
  • Amylase or lipase ≥ 1.5 times the within 14 days prior to maintenance treatment initiation
  • Serum albumin less than (\<) 2.5 grams per deciliter (g/dL)
  • LVEF \< institutional lower limit of normal or \< 50%, whichever is lower
  • Poorly controlled hypertension
  • Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage more than once every 28 days. Indwelling drainage catheters are allowed
  • Unstable angina, new onset angina within last 3 months, myocardial infarction within last 6 months and current congestive heart failure ≥ NYHA Grade 2
  • History of stroke, reversible ischemic neurological defect, or within 6 months prior to initiation of maintenance treatment
  • History or evidence of intracranial hemorrhage or spinal cord hemorrhage
  • Evidence of clinically significant vasogenic edema
  • Any hemorrhage or bleeding event ≥ National Cancer Institute Grade 3 within 28 days prior to initiation of maintenance treatment
  • History or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for central serous retinopathy, retinal vein occlusion, or neovascular macular degeneration
  • Positive HIV test
  • Active HBV or HCV
  • Active tuberculosis
  • Severe infection within 4 weeks prior to start of maintenance treatment including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia; has signs or symptoms of significant infection or has received oral or IV antibiotics within 2 weeks prior to start of maintenance treatment.
  • Prior allogeneic bone marrow transplantation or prior solid organ transplantation
  • Administration of a live, attenuated vaccine within 4 weeks prior to start of study maintenance treatment or anticipation that such a live attenuated vaccine will be required during the study
  • Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
  • Prior treatment with a mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) or ERK inhibitor
  • Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin-2) within 4 weeks or five half-lives of the drug, whichever is longer, prior to start of study maintenance treatment
  • Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to start of study maintenance treatment, or requirement for systemic immunosuppressive medications during the trial.
  • If receiving a RANKL inhibitor (for example, denosumab), unwilling to adopt alternative treatment such as (but not limited to) bisphosphonates, while receiving atezolizumab.
  • Consumption of foods, supplements or drugs that are potent cytochrome P450 3A4 () enzyme inducers or inhibitors ≤ 7 days before initiation of study maintenance treatment or expected concomitant use during maintenance treatment. These include St. John's wort or hyperforin (potent CYP3A4 enzyme inducer) and grapefruit juice (potent CYP3A4 enzyme inhibitor)
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,044 participants (actual)

Study arms

  • Other
    Cohort 1: Induction Phase (IP)

    Includes participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.

    Drug: FOLFOX induction regimen · Drug: Bevacizumab · Drug: 5-FU/LV

  • Other
    Cohort 2 (IP)

    Includes participants with BRAFwt. All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.

    Drug: FOLFOX induction regimen · Drug: Bevacizumab · Drug: 5-FU/LV

  • Other
    Cohort 3 (IP)

    Includes participants with human epidermal growth factor receptor 2 positive (HER2+). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.

    Drug: FOLFOX induction regimen · Drug: Bevacizumab · Drug: 5-FU/LV

  • Other
    Cohort 4 (IP)

    Includes participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.

    Drug: FOLFOX induction regimen · Drug: Bevacizumab · Drug: 5-FU/LV

  • Experimental
    Cohort 1 (Maintenance Phase[MP]):5-FU/LV,cetuximab,vemurafenib

    Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m\^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m\^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.

    Drug: Cetuximab · Drug: Vemurafenib · Drug: 5-FU/LV

  • Active comparator
    Cohort 1 Control (MP): 5-FU/LV or capecitabin, bevacizumab

    Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

    Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Bevacizumab

  • Experimental
    Cohort 2 (MP):5-FU/LV or capecitabine,bevacizumab,atezolizumab

    Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m\^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.

    Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Atezolizumab · Drug: Bevacizumab

  • Active comparator
    Cohort 2 Control (MP): 5-FU/LV or capecitabin, bevacizumab

    Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

    Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Bevacizumab

  • Experimental
    Cohort 3 (MP): capecitabine,trastuzumab,pertuzumab

    Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m\^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.

    Drug: Trastuzumab · Drug: Pertuzumab · Drug: Capecitabine

  • Active comparator
    Cohort 3 Control (MP): 5-FU/LV or capecitabin, bevacizumab

    Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

    Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Bevacizumab

  • Experimental
    Cohort 4 (MP): Cobimetinib,atezolizumab

    Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.

    Drug: Atezolizumab · Drug: Cobimetinib

  • Active comparator
    Cohort 4 Control (MP): 5-FU/LV or capecitabin, bevacizumab

    Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

    Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Bevacizumab

  • Other
    Early Progressing BRAFmut Cohort

    BRAFmut participants experiencing early disease progression during induction treatment will have the option of proceeding immediately to receive second-line treatment with 5-FU/LV, cetuximab and vemurafenib if their primary tumor is MSS, or with a fluoropyrimidine (5-FU/LV or capecitabine), bevacizumab, and atezolizumab if their primary tumor is MSI-H. This cohort will be followed for adverse events during the study, but is not part of the Maintenance Phase study objectives.

    Drug: Cetuximab · Drug: Fluoropyrimidine (5-FU/LV or capecitabine) · Drug: Atezolizumab · Drug: Vemurafenib · Drug: Bevacizumab · Drug: 5-FU/LV

Interventions

  • 500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle

  • DrugFOLFOX induction regimen

    Administered per the Investigator's discretion in accordance with locally approved prescribing information.

  • DrugFluoropyrimidine (5-FU/LV or capecitabine)

    Drug page: Fluoropyrimidine

    Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

  • 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg

    Also known as: MPDL3280A, RO5541267

  • 960 mg vermurafenib BID by mouth

    Also known as: RO5185426

  • 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

    Also known as: RO4876646

  • Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle

    Also known as: RO0452317

  • Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle

    Also known as: RO4368451

  • 60 mg orally once daily for 3 weeks followed by a 1-week treatment break

    Also known as: RO5514041

  • Drug5-FU/LV

    1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.

  • 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/=5 mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions.

    Time frame: From randomization until disease progression or death from any cause, up to 5 years

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization into the MTP to time of death from any cause.

    Time frame: From randomization until death from any cause, up to 5 years

  2. Percentage of Participants With Adverse Events

    Time frame: From baseline until end of study (up to 5 years)

  3. Overall Response

    Calculated as the number of participants with a best overall response of CR or PR according to RECIST 1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR= CR + PR.

    Time frame: From randomization until disease progression, up to 5 years

  4. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.

    Time frame: From randomization until disease progression, up to 5 years

  5. Time to Treatment Response

    Calculated as the time from randomization to the first Occurrence of a documented Objective Response (CR or PR) determined according to RECIST 1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: From randomization until disease progression or death from any cause, up to 5 years

  6. Duration of Response

    Defined as the time from the first assessment of CR or PR until disease progression or death from any cause, whichever occurs first. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: From first objective response until disease progression or death from any cause, up to 5 years

  7. Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score

    Time frame: From baseline until end of study (up to 5 years)

07

Results

Posted Jul 24, 2020

Participant flow

Induction Treatment
Participant flow — Induction Treatment
MilestoneCohort 1: Induction Phase (IP)Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 2 (IP)Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (IP)Cohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (IP)Cohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, BevacizumabEarly Progressing BRAFmut Cohort
Started930063500600310000
Treated during induction phase930063200600309000
Completed630046000500135000
Not completed300017500100175000
Withdrew: Withdrawal by subject000240000018000
Withdrew: Adverse event0003000001000
Withdrew: Death25001110010082000
Withdrew: Lost to follow-up10012000009000
Withdrew: Non-compliance0001000001000
Withdrew: Reason not specified0004000007000
Withdrew: Physician decision0003000001000
Withdrew: Protocol violation0003000002000
Withdrew: Missing400140000054000
Maintenance Treatment Phase
Participant flow — Maintenance Treatment Phase
MilestoneCohort 1: Induction Phase (IP)Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 2 (IP)Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (IP)Cohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (IP)Cohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, BevacizumabEarly Progressing BRAFmut Cohort
Started040200297148032065340
Treated during maintenance phase040180293143032064340
Completed0620662100101260
Not completed034180231127031053280
Withdrew: Withdrawal by subject000015120000230
Withdrew: Death029160188107011046190
Withdrew: Adverse event0000110000000
Withdrew: Lost to follow-up01001540100330
Withdrew: Reason not specified0000720100100
Withdrew: Physician decision0200300000130
Withdrew: Not treated0020000000000
Withdrew: Study ended by sponsor0100000000000
Withdrew: Non-compliance0100210000000
Early Disease Progression
Participant flow — Early Disease Progression
MilestoneCohort 1: Induction Phase (IP)Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 2 (IP)Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (IP)Cohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (IP)Cohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, BevacizumabEarly Progressing BRAFmut Cohort
Started00000000000011
Completed0000000000000
Not completed00000000000011
Withdrew: Death00000000000010
Withdrew: Lost to follow-up0000000000001

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS is defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of \>/=5 mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions.

Time frame:
From randomization until disease progression or death from any cause, up to 5 years
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsCohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab
Progression-Free Survival (PFS)9.99 (7.72 to 12.55)11.60 (3.58 to 15.67)7.13 (6.14 to 8.41)7.36 (5.82 to 8.94)4.44 (3.55 to 14.69)4.04 (4.04 to 5.39)3.75 (3.42 to 3.91)7.79 (3.98 to 9.46)
Statistical analysis
  • Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib vs Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = = 0.872 · Hazard ratio (hr): 0.95 · 95% CI 0.50 to 1.82
  • Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab vs Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = = 0.666 · Hazard ratio (hr): 0.95 · 95% CI 0.77 to 1.18
  • Cohort 4 (MP): Cobimetinib,Atezolizumab vs Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = = 0.128 · Hazard ratio (hr): 1.44 · 95% CI 0.90 to 2.29
SecondaryOverall Survival (OS)

OS is defined as the time from randomization into the MTP to time of death from any cause.

Time frame:
From randomization until death from any cause, up to 5 years
Reported as:
Median · months
Overall Survival (OS)
monthsCohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab
Overall Survival (OS)24.02 (16.07 to 34.00)21.73 (7.92 to 37.19)22.54 (20.04 to 26.87)22.24 (18.50 to 25.13)NA (NA to 16.07)14.59 (NA to NA)22.60 (14.23 to 27.40)25.17 (15.90 to 32.59)
Statistical analysis
  • Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib vs Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = = 0.276 · Hazard ratio (hr): 0.71 · 95% CI 0.39 to 1.32
  • Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab vs Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = = 0.076 · Hazard ratio (hr): 0.81 · 95% CI 0.64 to 1.02
  • Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab vs Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = = 0.157
  • Cohort 4 (MP): Cobimetinib,Atezolizumab vs Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = = 0.415 · Hazard ratio (hr): 1.25 · 95% CI 0.73 to 2.14
SecondaryPercentage of Participants With Adverse Events
Time frame:
From baseline until end of study (up to 5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsCohort 1: Induction Phase (IP)Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control: 5-FU/LV or Capecitabin, BevacizumabCohort 2 (IP)Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (IP)Cohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (IP)Cohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, BevacizumabEarly Progressing BRAFmut Cohort
Percentage of Participants With Adverse Events98.910094.496.095.688.110010010097.498.488.290.9
SecondaryOverall Response

Calculated as the number of participants with a best overall response of CR or PR according to RECIST 1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR= CR + PR.

Time frame:
From randomization until disease progression, up to 5 years
Reported as:
Count of participants · Participants
Overall Response
ParticipantsCohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control(MP): 5-FU/LV or Capecitabin, BevacizumabCohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab
Overall Response20549221078
Statistical analysis
  • Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib vs Cohort 1 Control(MP): 5-FU/LV or Capecitabin, Bevacizumab · Chi-squared · p = = 0.064
  • Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab vs Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Chi-squared · p = = 0.658
  • Cohort 4 (MP): Cobimetinib,Atezolizumab vs Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Chi-squared · p = 0.093
SecondaryDisease Control Rate (DCR)

DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.

Time frame:
From randomization until disease progression, up to 5 years
Reported as:
Count of participants · Participants
Disease Control Rate (DCR)
ParticipantsCohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control(MP): 5-FU/LV or Capecitabin, BevacizumabCohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab
Disease Control Rate (DCR)3615227111104426
Statistical analysis
  • Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib vs Cohort 1 Control(MP): 5-FU/LV or Capecitabin, Bevacizumab · Chi-squared · p = = 0.125
  • Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab vs Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Chi-squared · p = = 0.739
  • Cohort 4 (MP): Cobimetinib,Atezolizumab vs Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Chi-squared · p = 0.362
SecondaryTime to Treatment Response

Calculated as the time from randomization to the first Occurrence of a documented Objective Response (CR or PR) determined according to RECIST 1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
From randomization until disease progression or death from any cause, up to 5 years
Reported as:
Median · months
Time to Treatment Response
monthsCohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control(MP):5-FU/LV or Capecitabin, BevacizumabCohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab
Time to Treatment Response3.943 (1.18 to 29.70)5.552 (1.38 to 8.02)5.224 (1.22 to 26.74)4.616 (1.25 to 19.91)5.490 (5.490 to 5.490)0 (0 to 0)3.745 (1.77 to 14.92)2.530 (1.64 to 11.83)
SecondaryDuration of Response

Defined as the time from the first assessment of CR or PR until disease progression or death from any cause, whichever occurs first. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
From first objective response until disease progression or death from any cause, up to 5 years
Reported as:
Median · months
Duration of Response
monthsCohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control(MP):5-FU/LV or Capecitabin, BevacizumabCohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab
Duration of Response11.50 (7.66 to 21.49)8.74 (5.36 to 19.02)9.30 (5.55 to 11.30)7.59 (6.93 to 13.90)9.205 (9.205 to 9.205)0 (0 to 0)7.11 (1.48 to NA)6.06 (2.20 to 7.33)
Statistical analysis
  • Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib vs Cohort 1 Control(MP):5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = = 0.421
  • Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab vs Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = = 0.495
  • Cohort 4 (MP): Cobimetinib,Atezolizumab vs Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab · Log Rank · p = 0.357
SecondaryPercentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
Time frame:
From baseline until end of study (up to 5 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
percentage of participantsCohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control(MP):5-FU/LV or Capecitabin, BevacizumabCohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab
Improved10.05.010.45.4007.75.9
Improved or stayed the same75.085.076.782.510010063.179.4

Adverse events

Collected over From baseline until end of study (up to 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Induction Phase (IP)25/93 (26.9%)44/93 (47.3%)91/93 (97.8%)
Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib29/40 (72.5%)15/40 (37.5%)40/40 (100%)
Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab16/20 (80%)5/18 (27.8%)17/18 (94.4%)
Cohort 2 (IP)111/635 (17.5%)232/632 (36.7%)608/632 (96.2%)
Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab188/297 (63.3%)76/293 (25.9%)270/293 (92.2%)
Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab107/148 (72.3%)20/143 (14%)120/143 (83.9%)
Cohort 3 (IP)1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab1/3 (33.3%)0/3 (0%)3/3 (100%)
Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab1/2 (50%)0/2 (0%)2/2 (100%)
Cohort 4 (IP)82/310 (26.5%)93/309 (30.1%)298/309 (96.4%)
Cohort 4 (MP): Cobimetinib,Atezolizumab46/65 (70.8%)26/64 (40.6%)61/64 (95.3%)
Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab19/34 (55.9%)3/34 (8.8%)29/34 (85.3%)
Early Progressing BRAFmut Cohort10/11 (90.9%)3/11 (27.3%)11/11 (100%)
Most frequent serious events
Showing 10 of 227
Most frequent serious events
EventCohort 1: Induction Phase (IP)Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 2 (IP)Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (IP)Cohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (IP)Cohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, BevacizumabEarly Progressing BRAFmut Cohort
Colonic fistulaGastrointestinal disorders0/930/400/180/6320/2930/1431/60/30/20/3090/640/340/11
Abdominal painGastrointestinal disorders2/931/400/184/6321/2931/1430/60/30/26/3091/640/341/11
DiarrhoeaGastrointestinal disorders5/931/401/1813/6325/2932/1430/60/30/24/3092/640/341/11
GastroenteritisInfections and infestations1/930/400/183/6322/2930/1430/60/30/20/3090/640/341/11
DehydrationMetabolism and nutrition disorders3/930/400/183/6320/2930/1430/60/30/23/3091/640/341/11
IleusGastrointestinal disorders2/931/401/1810/6322/2930/1430/60/30/22/3090/640/340/11
Implant site thrombosisGeneral disorders1/930/401/180/6320/2930/1430/60/30/20/3090/640/340/11
CholestasisHepatobiliary disorders2/930/401/180/6320/2930/1430/60/30/20/3090/640/340/11
Abdominal wall abscessInfections and infestations2/930/401/180/6320/2930/1430/60/30/20/3090/640/340/11
Device related infectionInfections and infestations2/930/401/182/6321/2930/1430/60/30/20/3090/640/340/11
Most frequent other events
Showing 10 of 184
Most frequent other events
EventCohort 1: Induction Phase (IP)Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,VemurafenibCohort 1 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 2 (IP)Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,AtezolizumabCohort 2 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 3 (IP)Cohort 3 (MP): Capecitabine,Trastuzumab,PertuzumabCohort 3 Control (MP): 5-FU/LV or Capecitabin, BevacizumabCohort 4 (IP)Cohort 4 (MP): Cobimetinib,AtezolizumabCohort 4 Control (MP): 5-FU/LV or Capecitabin, BevacizumabEarly Progressing BRAFmut Cohort
EpistaxisRespiratory, thoracic and mediastinal disorders18/934/401/18121/63223/29316/1433/60/32/261/3096/643/343/11
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders16/935/404/1898/63244/29325/1434/63/30/219/3091/643/342/11
DiarrhoeaGastrointestinal disorders52/9316/404/18282/63278/29321/1434/62/30/2134/30940/648/345/11
FatigueGeneral disorders31/939/402/18247/63252/29323/1434/61/30/287/30912/647/343/11
NauseaGastrointestinal disorders53/9316/400/18298/63264/29327/1432/60/30/2129/30917/646/343/11
ConstipationGastrointestinal disorders23/935/400/18158/63238/29317/1432/60/31/258/3097/642/341/11
Gingival bleedingGastrointestinal disorders2/932/400/189/6325/2930/1431/60/31/20/3090/640/340/11
Mucosal inflammationGeneral disorders16/937/402/1869/63220/2937/1433/61/30/257/3094/641/342/11
Peripheral sensory neuropathyNervous system disorders26/934/401/18222/63232/29315/1433/60/30/258/3093/644/340/11
Skin exfoliationSkin and subcutaneous tissue disorders1/931/400/186/6325/2930/1431/60/31/20/3090/640/340/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1: Induction Phase (IP)Cohort 2 (IP)Cohort 3 (IP)Cohort 4 (IP)Total
Mean59.5 ± 12.060.9 ± 12.648.0 ± 7.760.1 ± 10.360.5 ± 11.9
Age, Customized
Age, Customized(Participants)Cohort 1: Induction Phase (IP)Cohort 2 (IP)Cohort 3 (IP)Cohort 4 (IP)Total
In utero00000
Preterm newborn infants (gestational age < 37 wks)00000
Newborns (0-27 days)00000
Infants and toddlers (28 days-23 months)00000
Children (2-11 years)00000
Adolescents (12-17 years)00000
Adults (18-64 years)583516199614
From 65-84 years352790110424
85 years and over05016
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Induction Phase (IP)Cohort 2 (IP)Cohort 3 (IP)Cohort 4 (IP)Total
Female492474123423
Male443882187621
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Induction Phase (IP)Cohort 2 (IP)Cohort 3 (IP)Cohort 4 (IP)Total
Hispanic or Latino552149107
Not Hispanic or Latino754944247820
Unknown or Not Reported1389114117
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Induction Phase (IP)Cohort 2 (IP)Cohort 3 (IP)Cohort 4 (IP)Total
American Indian or Alaska Native1901424
Asian51501636
Native Hawaiian or Other Pacific Islander00011
Black or African American0100515
White765396264885
More than one race00011
Unknown or Not Reported11620982
08

Study locations

154 sites
  • Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncología
    Buenos Aires, C1264AAA, Argentina
  • Centro Oncologico Riojano Integral (CORI)
    La Rioja, F5300COE, Argentina
  • Clínica Viedma
    Viedma Rio Negro, R8500ACE, Argentina
  • Institut Jules Bordet X
    Brussels, 1000, Belgium
  • Hospital Erasme
    Bruxelles, 1070, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • CHC MontLégia
    Liege, 4000, Belgium
  • AZ Delta (Campus Rumbeke)
    Roeselare, 8800, Belgium
  • University Clinical Center of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
  • Hospital da Cidade de Passo Fundo; Centro de Pesquisa em Oncologia
    Passo Fundo, RS 99010-260, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, RS 90035-903, Brazil
  • Hospital Nossa Senhora da Conceicao
    Porto Alegre, RS 91350-200, Brazil
  • Hospital de Cancer de Barretos
    Barretos, SP 14784-400, Brazil
  • Hospital Amaral Carvalho
    Jau, SP 17210-120, Brazil
  • Faculdade de Medicina de Sao Jose do Rio Preto - FAMERP*X*
    Sao Jose do Rio Preto, SP 15090-000, Brazil
  • Instituto de Ensino e Pesquisa Sao Lucas - IEP
    Sao Paulo, SP 01236-030, Brazil
  • Herlev Hospital; Afdeling for Kræftbehandling
    Herlev, 2730, Denmark
  • Regionshospitalet Gødstrup; Kræftafdelingen
    Herning, 7400, Denmark
  • Rigshospitalet; Onkologisk Klinik
    København Ø, 2100, Denmark
  • Odense Universitetshospital, Onkologisk Afdeling R
    Odense C, 5000, Denmark
  • Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium
    Roskilde, 4000, Denmark
  • National Cancer Institute
    Cairo, 11796, Egypt
  • Ain Shams University Hospital; Oncology
    Cairo, Egypt
  • Clinique Sainte Catherine
    Avignon, 84082, France
  • HOPITAL JEAN MINJOZ; Oncologie
    Besancon, 25030, France
  • Hopital Augustin Morvan; Federation De Cancerologie
    Brest, 29200, France
  • Chu Estaing; Chir Generale Digestive A Et B
    Clermont Ferrand, 63003, France
  • Hôpital Franco-Britannique- Fondation Cognacq-Jay; Cancerologie
    Levallois-Perret, 92300, France
  • Hopital Claude Huriez; Medecine Interne Oncologie
    Lille, 59037, France
  • Ch De Montbeliard;Chir Generale Digestive
    Montbeliard, 25209, France
  • Hopital Caremeau; Gastro Enterologie
    Nimes, 30029, France
  • Hopital Saint Antoine; Oncologie Medicale
    Paris, 75571, France
  • Hopital Haut Leveque
    Pessac, 33600, France
  • Chu La Miletrie; Gastro Enterologie Endoscopies
    Poitiers, 86021, France
  • ICANS
    Strasbourg, 67200, France
  • Hopital Rangueil; Gastro Enterologie Et Nutrition
    Toulouse, 31059, France
  • Institut Gustave Roussy; Departement Oncologie Medicale
    Villejuif, 94805, France
  • Hämatologie Onkologie im Zentrum MVZ GmbH
    Augsburg, 86150, Germany
  • Onkologische Schwerpunktpraxis Kurfürstendamm
    Berlin, 10707, Germany
  • DRK Kliniken Berlin Köpenick Darmzentrum
    Berlin, 12559, Germany
  • BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie
    Dresden, 01307, Germany
  • Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie
    Frankfurt, 60488, Germany
  • PIOH PD Dr. R. Schnell ? Dr. H. Schulz ? Dr. M. Hellmann
    Frechen, 50226, Germany
  • Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH
    Fulda, 36043, Germany
  • Universitätsklinikum Hamburg-Eppendorf, Onkologisches Zentrum, Studienzentrale der II. Med. Klinik
    Hamburg, 20246, Germany
  • Medizinische Hochschule Hannover; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie
    Hannover, 30625, Germany
  • SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm.
    Heilbronn, 74078, Germany
  • Klinik der Ruhr-Uni Bochum; Marien-Hospital Herne
    Herne, 44625, Germany
  • Gemeinschaftspraxis für Hämatologie und Onkologie, PD Dr. Bauer, Dr. Thiel
    Lebach, 66822, Germany
  • Onkologische Gemeinschaftspraxis
    Magdeburg, 39104, Germany
  • Klinikum Magdeburg gGmbH Klinik für Allgemein- und Viszeralchirurgie
    Magdeburg, 39130, Germany
  • Universitätsklinikum Magdeburg Klinik für Gastroenterologie und Hepatologie
    Mageburg, 39120, Germany
  • Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus
    Mönchengladbach, 41063, Germany
  • Städt. Klinikum München GmbH Klinikum Neuperlach Klinik f.Hämatologie u.Onkologie
    München, 81737, Germany
  • Gemeinschaftspraxis für Hämatologie und Onkologie
    Münster, 48153, Germany
  • Brüderkrankenhaus St. Josef
    Paderborn, 33098, Germany
  • Studienzentrum Onkologie Ravensburg GbR; Onkologie Ravensburg
    Ravensburg, 88212, Germany
  • Prosper-Hospital, Medizinische Klinik I
    Recklinghausen, 45659, Germany
  • Krankenhaus Barmherziger Brüder; Klinik für Internistische Onkologie / Hämatologie
    Regensburg, 93049, Germany
  • Klinikum am Steinenberg / Ermstalklinik
    Reutlingen, 72764, Germany
  • Praxis für Hämatologie & Onkologie
    Saarbruecken, 66113, Germany
  • MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
    Stade, 21680, Germany
  • Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie
    Trier, 54290, Germany
  • Klinikum Wetzlar-Braunfels, Klinik für Hämatologie/Onkologie und Palliativmedizin
    Wetzlar, 35578, Germany
  • Agioi Anargyroi; 3Rd Dept. of Medical Oncology
    Athens, 145 64, Greece
  • Univ General Hosp Heraklion; Medical Oncology
    Heraklion, 711 10, Greece
  • Uni Hospital of Ioannina; Oncology Dept.
    Ioannina, 455 00, Greece
  • University Hospital of Patras Medical Oncology
    Patras, 265 04, Greece
  • Thermi Clinic; Oncology Clinic
    Thermi Thessalonikis, 570 01, Greece
  • Bioclinic Thessaloniki
    Thessaloniki, 546 22, Greece
  • Euromedical General Clinic of Thessaloniki; Oncology Department
    Thessaloniki, 546 45, Greece
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A
    Napoli, Campania 80131, Italy
  • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
    Meldola, Emilia-Romagna 47014, Italy
  • A.O. Universitaria Di Parma; Oncologia Medica
    Parma, Emilia-Romagna 43100, Italy
  • Istituto Regina Elena; Oncologia Medica A
    Roma, Lazio 00168, Italy
  • Policlinico Universitario "Agostino Gemelli"; U.O.C. Oncologia Medica
    Roma, Lazio 00168, Italy
  • Humanitas Gavazzeni;U.O. Oncologia Medica
    Bergamo, Lombardia 24121, Italy
  • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
    Milano, Lombardia 20133, Italy
  • Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica
    Milano, Lombardia 20141, Italy
  • Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
    Milano, Lombardia 20162, Italy
  • IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia
    San Giovanni Rotondo, Puglia 71013, Italy
  • Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1
    Firenze, Toscana 50139, Italy
  • IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima
    Padova, Veneto 35128, Italy
  • A.O.U.I. VERONA-OSPEDALE POLICLINICO G.B. ROSSI BORGO ROMA;ONCOLOGIA MEDICA-d.U.
    Verona, Veneto 37134, Italy
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Fundacion Rodolfo Padilla Padilla A.C.
    León, Guanajuato 37000, Mexico
  • Oaxaca Site Management Organization
    Oaxaca de Juárez, Oaxaca 68000, Mexico
  • Cancerologia de Queretaro; Oncologia
    Queretaro, Queretaro, Queretaro 76090, Mexico
  • Instituto Nacional de Cancerologia; Oncology
    Mexico City, 14080, Mexico
  • Antoni van Leeuwenhoek Ziekenhuis
    Amsterdam, 1066 CX, Netherlands
  • Ijsselland Ziekenhuis; Inwendige Geneeskunde
    Capelle A/d IJssel, NL 2900 AR, Netherlands
  • Deventer Ziekenhuis; Interne Geneeskunde
    Deventer, 7416 SE, Netherlands
  • Albert Schweitzer Ziekenhuis - loc Dordrecht
    Dordrecht, 3318 AT, Netherlands
  • Catharina ZKHS; Inwendige Geneeskunde Afd.
    Eindhoven, 5623 EJ, Netherlands
  • St. Antonius locatie Leidsche Rijn
    Utrecht, 3543 AZ, Netherlands
  • Isala Klinieken
    Zwolle, 8011 JW, Netherlands
  • Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii
    Kraków, 30-688, Poland

Showing the first 100 of 154 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in May 2019, 49 months.

Results were first posted in Jul 2020, 1 year 1 month after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 49 months is above that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2014
First posted
Nov 14, 2014
StartActual
Apr 17, 2015
Primary completionActual
May 31, 2019
CompletionActual
Mar 24, 2021
Results first posted
Jul 24, 2020
Last update
May 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02291289
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 14, 2014
Start date
Apr 17, 2015
Primary completion
May 31, 2019
Completion
Mar 24, 2021
Results posted
Jul 24, 2020
Last update
May 6, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Fluoropyrimidine · Atezolizumab · Vemurafenib · Bevacizumab · Trastuzumab · Pertuzumab · Cobimetinib · Capecitabine

Start the discussion